Trials / Recruiting
RecruitingNCT05944224
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
A Randomized, Open-label, Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors, Including Advanced Well Differentiated/Dedifferentiated Liposarcoma.
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH4336 | SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle |
| DRUG | Cadonilimab | Intravenous infusion, 6mg/Kg,28 days/cycle |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2026-05-31
- Completion
- 2026-12-31
- First posted
- 2023-07-13
- Last updated
- 2026-01-13
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05944224. Inclusion in this directory is not an endorsement.